These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31928169)

  • 61. [Evaluation of the medical treatment of Graves' disease (GD)].
    Peixoto MC; Coeli CM; Vaisman M
    Arq Bras Endocrinol Metabol; 2005 Jun; 49(3):410-9. PubMed ID: 16543996
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The change in 123I-uptake between 3- and 24-hours is useful in predicting early response to methimazole in patients with Graves' disease.
    Gemma R; Nakamura H; Mori T; Andoh S; Suzuki Y; Yoshimi T
    Endocr J; 1996 Feb; 43(1):61-6. PubMed ID: 8732453
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prediction for recurrence following antithyroid drug therapy for Graves' hyperthyroidism.
    Weng H; Tian WB; Xiao ZD; Xu L
    Arch Endocrinol Metab; 2023 May; 67(4):e000609. PubMed ID: 37252698
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Response to methimazole in Graves' disease. The European Multicenter Study Group.
    Benker G; Vitti P; Kahaly G; Raue F; Tegler L; Hirche H; Reinwein D
    Clin Endocrinol (Oxf); 1995 Sep; 43(3):257-63. PubMed ID: 7586593
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial.
    Leo M; Bartalena L; Rotondo Dottore G; Piantanida E; Premoli P; Ionni I; Di Cera M; Masiello E; Sassi L; Tanda ML; Latrofa F; Vitti P; Marcocci C; Marinò M
    J Endocrinol Invest; 2017 Mar; 40(3):281-287. PubMed ID: 27734319
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Thyroid hypoechogenicity after methimazole withdrawal in Graves' disease: a useful index for predicting recurrence?
    Zingrillo M; D'Aloiso L; Ghiggi MR; Di Cerbo A; Chiodini I; Torlontano M; Liuzzi A
    Clin Endocrinol (Oxf); 1996 Aug; 45(2):201-6. PubMed ID: 8881453
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Immunomodulatory role of vitamin D and selenium supplementation in newly diagnosed Graves' disease patients during methimazole treatment.
    Gallo D; Bruno A; Gallazzi M; Cattaneo SAM; Veronesi G; Genoni A; Tanda ML; Bartalena L; Passi A; Piantanida E; Mortara L
    Front Endocrinol (Lausanne); 2023; 14():1145811. PubMed ID: 37124743
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease.
    Kawakami-Tani T; Fukawa E; Tanaka H; Abe Y; Makino I
    Metabolism; 1997 Oct; 46(10):1184-8. PubMed ID: 9322804
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Therapeutic efficacy and limitations of potassium iodide for patients newly diagnosed with Graves' disease.
    Suzuki N; Yoshimura Noh J; Sugisawa C; Hoshiyama A; Hiruma M; Kawaguchi A; Morisaki M; Ohye H; Suzuki M; Matsumoto M; Kunii Y; Yoshihara A; Watanabe N; Sugino K; Ito K
    Endocr J; 2020 Jun; 67(6):631-638. PubMed ID: 32188795
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Maternal hyperthyroidism and congenital malformation in the offspring.
    Momotani N; Ito K; Hamada N; Ban Y; Nishikawa Y; Mimura T
    Clin Endocrinol (Oxf); 1984 Jun; 20(6):695-700. PubMed ID: 6467634
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of thyroxine administration on serum thyrotropin receptor antibody and thyroglobulin levels in patients with Graves' hyperthyroidism during antithyroid drug therapy.
    Kuo SW; Huang WS; Hu CA; Liao WK; Fung TC; Wu SY
    Eur J Endocrinol; 1994 Aug; 131(2):125-30. PubMed ID: 8075781
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Development of primary hypothyroidism with the appearance of blocking-type antibody to thyrotropin receptor in Graves' disease in late pregnancy.
    Ueta Y; Fukui H; Murakami H; Yamanouchi Y; Yamamoto R; Murao A; Santou Y; Taniguchi S; Mitani Y; Shigemasa C
    Thyroid; 1999 Feb; 9(2):179-82. PubMed ID: 10090319
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Use of antihistamines after serious allergic reaction to methimazole in pediatric Graves' disease.
    Toderian AB; Lawson ML
    Pediatrics; 2014 May; 133(5):e1401-4. PubMed ID: 24777217
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Metabolite Changes during the Transition from Hyperthyroidism to Euthyroidism in Patients with Graves' Disease.
    Lee HY; Sim BC; Nga HT; Moon JS; Tian J; Linh NT; Ju SH; Choi DW; Setoyama D; Yi HS
    Endocrinol Metab (Seoul); 2022 Dec; 37(6):891-900. PubMed ID: 36604959
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Impact of methimazole treatment on magnesium concentration and lymphocytes activation in adolescents with Graves' disease.
    Klatka M; Grywalska E; Partyka M; Charytanowicz M; Rolinski J
    Biol Trace Elem Res; 2013 Jun; 153(1-3):155-70. PubMed ID: 23661330
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily.
    Takata K; Kubota S; Fukata S; Kudo T; Nishihara E; Ito M; Amino N; Miyauchi A
    Thyroid; 2009 Jun; 19(6):559-63. PubMed ID: 19445623
    [TBL] [Abstract][Full Text] [Related]  

  • 77. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.
    Kahaly GJ; Bartalena L; Hegedüs L; Leenhardt L; Poppe K; Pearce SH
    Eur Thyroid J; 2018 Aug; 7(4):167-186. PubMed ID: 30283735
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy of low-dose methimazole in control of multiple relapses of Graves' hyperthyroidism: a case report.
    Azizi F; Amouzegar A; Abdi H
    J Med Case Rep; 2021 Apr; 15(1):189. PubMed ID: 33888159
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
    Nakazato N; Yoshida K; Mori K; Kiso Y; Sayama N; Tani JI; Nakagawa Y; Ito S
    Thyroid; 1999 Aug; 9(8):775-9. PubMed ID: 10482369
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment.
    Reinwein D; Benker G; Lazarus JH; Alexander WD
    J Clin Endocrinol Metab; 1993 Jun; 76(6):1516-21. PubMed ID: 8501160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.